2H51 Stock Chart & Stats
€1.69
-€0.04(-4.59%)
At close: 4:00 PM EST
€1.69
-€0.04(-4.59%)
Day’s Range― - ―
52-Week Range€0.80 - €2.35
Previous CloseN/A
Volume2.08K
Average Volume (3M)6.04K
Market Cap
€435.82M
Enterprise Value€417.82M
Total Cash (Recent Filing)€31.86M
Total Debt (Recent Filing)€33.30M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Jul 31, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding338,521,850
10 Day Avg. Volume5,698
30 Day Avg. Volume6,040
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.48Price Target Upside401.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.19
Revenue Forecast (FY)€3.76M
Bulls Say, Bears Say
Bulls Say
Late-stage Ophthalmic PipelineOcugen has multiple late-stage ophthalmic programs with completed enrollments and positive 12‑month Phase 2 data showing a 31% lesion reduction. Successful regulatory submissions or approvals would create durable, one-time gene therapy revenue streams and reposition the company from research to potential commercial execution.
Extended Cash Runway Via Convertible NotesThe $130M convertible notes issuance materially improves near‑term liquidity, repays higher‑cost debt and extends runway into 2028. This financing reduces immediate refinancing pressure, supports late‑stage development and planned regulatory filings, and provides time to de‑risk programs before needing new capital.
Governance And Clinical Leadership ContinuityBoard elections, auditor ratification and formal appointment of the CMO strengthen governance and clinical oversight. Stable leadership and independent audit support consistent regulatory interactions, trial execution and investor confidence—important for long‑term development and commercialization of complex gene therapies.
Bears Say
Persistent Operating LossesThe company remains deeply unprofitable with recurring negative operating and free cash flow across periods. Sustained cash burn forces ongoing dependence on external financing and creates execution risk if future capital markets access or milestone funding becomes constrained, limiting long‑term financial resilience.
Stressed Balance Sheet And Negative EquityRising leverage and negative trailing equity in 2025 signal weakened solvency and reduced buffers against adverse outcomes. High debt-to-equity and declining assets constrain strategic optionality, increase refinancing vulnerability and heighten risk of dilutive or expensive future financings over the medium term.
Dilution Risk From Convertible NotesThe convertible issuance improves liquidity but creates meaningful potential equity dilution if conversions occur. Dilution can materially erode existing shareholders' stake and reduce per‑share economics from future drug revenues, and conversion terms may affect capital structure and incentives over multiple years.
Ocugen News
2H51 FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was €0.80 and its highest was €2.35 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is €435.82M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Jul 31, 2026 which is in 20 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on May 05, 2026. The company reported -€0.053 earnings per share for the quarter, missing the consensus estimate of -€0.045 by -€0.008.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.05.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 338,521,850 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -€0.053 in its last earnings report, missing expectations of -€0.045. Following the earnings report the stock price went down -20.867%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in DE:2H51
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.48 (401.50% Upside)
€8.48 (401.50% Upside)
Blogger Sentiment
Bullish
DE:2H51 Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth €22.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.08%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-11.72%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
2H51 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and operational progress across multiple gene‑therapy programs (OCU400, OCU410, OCU410ST) including completed Phase 3 enrollment, strong early efficacy signals (46% lesion reduction, 50% responder rate, ~two-line LLVA gain, 60% slower EZ loss), a peer‑reviewed publication, a regional licensing deal, recent capital raise, and senior hires to support commercialization. Counterbalancing these positives are a limited cash runway into 2026 (dependence on uncertain warrant exercise and future financings), rising R&D spend (~24% year) and small/preliminary datasets that require confirmatory Phase 3 results. Overall, the highlights (clinical progress, regulatory alignment, partnerships, fundraising, leadership additions) meaningfully outweigh the risks, though execution and financing remain key near‑term priorities.View all DE:2H51 earnings summaries2H51 Stock 12 Month Forecast
Average Price Target
€8.48
▲(401.50% Upside)
Technical Analysis
Sinovac Biotech
―
XOMA Royalty Corporation
―
ADC Therapeutics
―
Monte Rosa Therapeutics
―
AbSci
―
Options Prices
Currently, No data available
---